SCHEMBL6014497

SCHEMBL6014497

CCOC(=O)c1ccccc1N(Cc1ccncc1)C(C)=O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TSHR P16473 2/20 0.49
▸ ALDH1A1 P00352 3/20 0.43
▸ HSD17B10 Q99714 1/20 0.43
▸ MAPK1 P28482 2/20 0.43
▸ LTB4R2 Q9NPC1 1/20 0.43
▸ SMN1; SMN2 Q16637 1/20 0.43
▸ HPGD P15428 1/20 0.42
▸ NPSR1 Q6W5P4 1/20 0.42
▸ KMT2A Q03164 3/20 0.41
▸ MEN1 O00255 2/20 0.41
▸ LMNA P02545 1/20 0.41
▸ CDC7 O00311 3/20 0.41
▸ DBF4 Q9UBU7 3/20 0.41
▸ L3MBTL1 Q9Y468 1/20 0.41
▸ TP53 P04637 1/20 0.40
▸ ATM Q13315 1/20 0.40
▸ MMP13 P45452 1/20 0.40
▸ NPC1 O15118 1/20 0.40
▸ RAB9A P51151 1/20 0.40
▸ TSPO P30536 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6683811 0.76 TSHR (0.54) TSHRALDH1A1HSD17B10MAPK1SMN1; SMN2
SCHEMBL7296075 0.74 TSHR (0.59) TSHRALDH1A1HSD17B10MAPK1SMN1; SMN2
SCHEMBL4838619 0.73 TSHR (0.57) TSHRALDH1A1HSD17B10KMT2AMEN1
SCHEMBL29387070 0.72 TSHR (0.69) TSHRALDH1A1HSD17B10MAPK1SMN1; SMN2
SCHEMBL180024 0.72 TSHR (0.69) TSHRALDH1A1HSD17B10MAPK1SMN1; SMN2
SCHEMBL1479808 0.71 TSHR (0.62) TSHRALDH1A1HSD17B10SMN1; SMN2KMT2A
SCHEMBL13279033 0.71 KDM4E (0.44) TSHRALDH1A1HSD17B10LTB4R2HPGD
Ammonia Solution, Strong SCHEMBL10715942 0.70 TSHR (0.67) TSHRALDH1A1HSD17B10MAPK1SMN1; SMN2
SCHEMBL3454897 0.70 TSHR (0.67) TSHRALDH1A1HSD17B10MAPK1NPSR1
SCHEMBL6014596 0.70 ADRA1D (0.61) TSHRALDH1A1HSD17B10MAPK1NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1633712-B1 SIX MEMBERED AMINO-AMIDE DERIVATIVES AS ANGIOGENESIS INHIBITORS CHEN GUOQING PAUL (US) 2014-06-25 — — EP disclosed
US-7129252-B2 Six membered amino-amide derivatives an angiogenisis inhibitors HLB CO., LTD. (KR) 2006-10-31 — — US disclosed
EP-1633712-A2 SIX MEMBERED AMINO-AMIDE DERIVATIVES AS ANGIOGENESIS INHIBITORS Chen, Guoqing Paul (US) 2006-03-15 — — EP disclosed
WO-2005000232-A2 SIX MEMBERED AMINO-AMIDE DERIVATIVES AS ANGIOGENESIS INHIBITORS CHEN GUOQING PAUL (US) 2005-01-06 — — WO disclosed
US-20040259916-A1 Six membered amino-amide derivatives an angiogenisis inhibitors HLB CO., LTD. (KR) 2004-12-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040259916-A1 Six membered amino-amide derivatives an angiogenisis inhibitors TEK, FLT1, VEGFA TSHR 4788/4885ALDH1A1 3087/4885HSD17B10 4767/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback